Author:
Mamtani Ronac,Tsingas Konstantinos,Parikh Ravi B.,Elsouda Dina,Mucha Lisa,Fuldeore Rupali,Hubbard Rebecca A.
Reference7 articles.
1. Enfortumab vedotin in previously treated advanced urothelial carcinoma;Powles;N Engl J Med,2021
2. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial;Yu;Lancet Oncol,2021
3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s0 00lbl.pdf. Accessed.
4. Development and validation of a high-quality composite real-world mortality endpoint;Curtis;Health Serv Res,2018
5. Ma X, Long L, Moon S, Adamson B, Baxi S. Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. medRxiv. In:2020.